ER+, HER2- MBC: Role of Everolimus in Current Landscape
Panelists discuss that although the use of everolimus has declined with newer targeted therapies, it remains an important option for patients without ESR1 mutations or PI3K/AKT pathway alterations, improving outcomes when endocrine therapy alone is ineffective and serving as a valuable alternative in later treatment lines when other targeted agents are unsuitable.
The use of Eeverolimus has decreased somewhat with the introduction of newer targeted agents, but it still holds a valuable place in treatment for certain patients. Specifically, it is considered for those who do not have ESR1 mutations or PI3K/AKT pathway alterations. In these cases, single-agent endocrine therapy alone tends to have poor efficacy, with progression-free survival often under three 3 months. Therefore, adding Eeverolimus can improve outcomes compared to with endocrine therapy by itself.
Everolimus is often reintroduced in situations where the newer targeted agents are not suitable or are unavailable, providing an important alternative in the treatment sequence. Its use may be more common in later lines of therapy when options become limited. Despite newer agents gaining prominence due to their targeted mechanisms and improved tolerability, Eeverolimus remains a useful tool in the therapeutic arsenal, particularly for patients lacking specific actionable mutations.
Overall, while Eeverolimus is used less frequently than before, it continues to be relevant for selected patients. Its role is defined by the tumor’s molecular profile and the treatment history, and it offers a meaningful benefit when endocrine therapy alone is insufficient. This highlights the importance of personalized treatment strategies, where multiple options exist to tailor therapy to individual patient needs.
